山东新华医疗器械股份有限公司控股股东增持计划终止公告详解

公告要点

• 控股股东山东健康集团原计划在2025年5月27日至2026年5月26日期间增持新华医疗股份，金额区间为人民币1亿元至2亿元。
• 截至2026年5月15日，山东健康集团累计增持657.43万股，增持金额为98,948,604.33元，已完成增持计划下限的98.95%。
• 增持后山东健康集团持股比例达到29.9944%。
• 因继续增持将导致持股比例触及或超过30%，触发要约收购义务，山东健康集团决定终止增持计划。
• 终止原因并非资金问题或履约意愿不足，而为遵守《上市公司收购管理办法》相关规定，属于客观规则限制下的审慎选择。
• 山东健康集团对新华医疗未来发展前景及投资价值仍持坚定信心，后续将持续通过资源协同、战略赋能等方式支持公司发展。
• 本次终止增持计划不会影响公司股权分布及控制权稳定性。

投资者需要关注的重点

1. 增持计划接近完成但未达下限：控股股东增持金额距离计划下限仅差1.05%，但因持股比例接近30%，被迫终止增持。投资者需关注这类增持终止对市场情绪的影响。
2. 要约收购触发风险：若控股股东持股比例达到或超过30%，将触发要约收购义务，这可能带来股权结构变动或价格波动。控股股东审慎终止增持，避免触发这一义务，有助于公司控制权稳定。
3. 控股股东对公司长期看好：虽增持计划受限终止，但山东健康集团明确表示将继续支持公司发展，投资者可据此判断控股股东对公司未来的信心。
4. 增持计划终止对股价影响：增持计划终止可能引发部分投资者担忧，但控股股东持股比例已接近30%，且终止原因为监管限制，非资金或意愿问题，市场可理性看待。
5. 公司股权结构稳定：公告明确终止增持不会导致股权分布不符合上市条件，也不会影响公司控制权稳定性。投资者可安心公司治理结构。

详细解读

山东新华医疗器械股份有限公司于2025年5月27日公告控股股东山东健康集团拟在未来一年内增持公司股份，金额在1亿元至2亿元之间。截止2026年5月15日，山东健康集团通过上海证券交易所集中竞价方式累计增持657.43万股，增持金额98,948,604.33元，已完成增持计划金额区间下限的98.95%。增持后持有股份总数达到181,959,527股，持股比例达29.9944%。

根据《上市公司收购管理办法》，若控股股东持股比例达到或超过30%，则需履行要约收购义务。这一义务将导致控股股东需向其他股东发出收购要约，有可能带来股权结构变化和公司控制权调整。为避免触发这一规定，山东健康集团选择终止增持计划。

山东健康集团强调终止增持并非由于资金筹措或履约意愿问题，而是合规审慎选择。集团继续看好新华医疗的核心竞争力和发展前景，后续将通过资源协同、战略赋能等方式支持公司和全体股东共同分享成长收益。

此次终止增持不会导致公司股权分布不符合上市条件，也不会对控制权稳定性产生影响。投资者应理性看待增持计划终止，关注公司长期发展和控股股东的持续支持。

免责声明

本报道仅供参考，内容基于公司公告。投资者请结合自身风险偏好和市场情况，谨慎决策。本文不构成任何投资建议。

English Version

Detailed Analysis of Termination of Share Increase Plan by Shandong Xinhua Medical Device Co., Ltd. Controlling Shareholder

Key Points

• Shandong Health Group, the controlling shareholder, originally planned to increase its holding of Xinhua Medical shares between May 27, 2025, and May 26, 2026, with an amount between RMB 100 million and 200 million.
• As of May 15, 2026, Shandong Health Group had accumulated an increase of 6,574,300 shares, with an increase amount of RMB 98,948,604.33, completing 98.95% of the lower limit of the planned amount.
• After the increase, Shandong Health Group’s shareholding ratio reached 29.9944%.
• Further increases would trigger a mandatory tender offer obligation as the shareholding would reach or exceed 30%. To avoid this, Shandong Health Group decided to terminate the plan.
• The termination is not due to funding or willingness issues, but is a prudent compliance decision based on regulatory restrictions.
• Shandong Health Group remains confident in Xinhua Medical’s long-term prospects and will continue to support the company through resource coordination and strategic empowerment.
• The termination does not affect the company’s shareholding structure or control stability.

Important Information for Investors

1. Increase Plan Nearly Completed but Not Fully: The controlling shareholder’s increase amount is only 1.05% short of the lower limit, but had to be terminated due to regulatory thresholds. Investors should monitor how this affects market sentiment.
2. Tender Offer Trigger Risk: If the controlling shareholder’s shareholding reaches or exceeds 30%, a mandatory tender offer must be made, possibly causing changes in shareholding structure and price fluctuations. The prudent termination avoids this risk and maintains control stability.
3. Long-term Confidence from Controlling Shareholder: Although the increase plan is terminated, Shandong Health Group expresses continued support for the company, indicating strong confidence in its future.
4. Impact on Share Price: Terminating the increase plan may cause investor concern, but since the reason is regulatory and not financial or willingness related, the market may respond rationally.
5. Shareholding Structure Stability: The announcement states that the termination will not make the shareholding distribution unqualified for listing nor affect control stability, reassuring investors regarding governance.

Detailed Interpretation

Shandong Xinhua Medical Device Co., Ltd. announced on May 27, 2025, that its controlling shareholder, Shandong Health Group, planned to increase its shareholding by RMB 100-200 million within one year. By May 15, 2026, Shandong Health Group had increased its holdings by 6,574,300 shares, totaling RMB 98,948,604.33, reaching 98.95% of the lower limit. Post-increase, it holds 181,959,527 shares or 29.9944% of the total.

Per regulations, if the controlling shareholder’s holdings reach or exceed 30%, it must make a mandatory tender offer, potentially causing changes in shareholding structure and control. To avoid this, Shandong Health Group prudently terminated the plan.

The group clarified that the termination is not due to funding or willingness, but is a compliance-driven decision. It remains confident in Xinhua Medical’s prospects and will continue to support the company through resource coordination and strategic empowerment.

This termination will not affect the company’s shareholding distribution or control stability. Investors should view this rationally and focus on the company’s long-term growth and the controlling shareholder’s continued support.

Disclaimer

This article is for reference only, based on company announcements. Investors should make decisions carefully based on their own risk appetite and market conditions. This article is not investment advice.

View 新华医疗 Historical chart here